Close Menu

NEW YORK (GenomeWeb) – German cancer diagnostics firm Sividon Diagnostics plans to expand its business by taking its EndoPredict breast cancer relapse prognostic test to the US and China.

Sividon, a 2010 spinoff from Siemens Healthcare Diagnostics based in Cologne, has been selling EndoPredict to pathology laboratories in Germany and elsewhere, mostly in Europe. The test combines gene expression profiling on a quantitative real-time PCR platform with standard prognostic factors and received the CE mark in late 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.